Abstract: Alzheimer's disease(AD) is a common neurodegenerative disease characterized by cognitive decline. The clinical impairment of memory, language and cognitive ability is mainly caused by β-amyloid(Aβ) deposition and hyperphosphorylation of tau. Cannabidiol(CBD), a specific terpenoid secondary metabolite in cannabis, does not produce neurodependence. It has neuroprotective, antioxidant and anti-inflammatory properties, and is also effective in vivo. In recent years, CBD has become a research hotspot for the treatment of AD. This article summarizes the research progress of CBD activities in AD models in vitro and in vivo, so as to provide reference and thought for future research on related new drugs.